Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
06 October 2016Next earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:53:03 GMTDividend
Analysts recommendations
Institutional Ownership
RSLS Latest News
ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET featuring Michael Miller, Paul Hickey, and Thomas Stankovich. Thank you for joining the call. Now I will hand it over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (Nasdaq: RSLS), a leading company specializing in weight loss and metabolic health solutions, will release its financial results for the first quarter of 2024 and provide a corporate update on Wednesday, May 15, 2024, after the market closes.
ReShape Lifesciences (NASDAQ: RSLS ) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for a PMA supplement. That a PMA supplement applies to the company's Lap-Band 2.0 FLEX.
ReShape Lifesciences (NASDAQ:RSLS) saw its stock soar, up 41% to 36 cents a share in premarket, after the micro-cap firm's latest obesity treatment, Lap-Band 2.0, was approved by the US Food and Drug Administration (FDA). The FDA provided the company with a PMA supplement approval for the new generation of ReShape's Lap-Band – described as a “minimally invasive alternative to surgical stapling procedures – which features ‘FLEX' technology that the company said acts as a ‘relief valve' allowing larger pieces of food to move more easily through the narrower passage created by the band.
Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023
Reshape Lifesciences (NASDAQ: RSLS ) stock is getting a boost on Wednesday without any clear news from the medical device company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rallying today.
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Michael Miller - Rx Communications, IR Paul Hickey - President and CEO Tom Stankovich - CFO Christine Ren-Fielding - Member, ReShape Scientific Advisory Board Conference Call Participants Anthony Vendetti - Maxim Operator Good afternoon, and thank you for joining the ReShape Lifesciences Second Quarter 2023 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q4 2022 Earnings Conference Call April 25, 2023 4:30 PM ET Company Participants Michael Miller - Investor Relations Paul Hickey - President & Chief Executive Officer Thomas Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences' Year-End 2022 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled for 8:00 am ET on March 29, 2022. The delay is required to allow the company additional time to complete its year end audited financial information.
What type of business is ReShape Lifesciences?
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
What sector is ReShape Lifesciences in?
ReShape Lifesciences is in the Healthcare sector
What industry is ReShape Lifesciences in?
ReShape Lifesciences is in the Medical Devices industry
What country is ReShape Lifesciences from?
ReShape Lifesciences is headquartered in United States
When did ReShape Lifesciences go public?
ReShape Lifesciences initial public offering (IPO) was on 06 October 2016
What is ReShape Lifesciences website?
https://www.reshapelifesciences.com
Is ReShape Lifesciences in the S&P 500?
No, ReShape Lifesciences is not included in the S&P 500 index
Is ReShape Lifesciences in the NASDAQ 100?
No, ReShape Lifesciences is not included in the NASDAQ 100 index
Is ReShape Lifesciences in the Dow Jones?
No, ReShape Lifesciences is not included in the Dow Jones index
When does ReShape Lifesciences report earnings?
The next expected earnings date for ReShape Lifesciences is 07 August 2024